WO2006034327A1 - Medicinal disulfide salts - Google Patents
Medicinal disulfide salts Download PDFInfo
- Publication number
- WO2006034327A1 WO2006034327A1 PCT/US2005/033774 US2005033774W WO2006034327A1 WO 2006034327 A1 WO2006034327 A1 WO 2006034327A1 US 2005033774 W US2005033774 W US 2005033774W WO 2006034327 A1 WO2006034327 A1 WO 2006034327A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- group
- alkylene
- ion
- bond
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/66—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- the present invention relates to novel salts of certain disulfide, compounds. More specifically, the invention relates to pharmaceutical salts of dithio(alkane sulfonate) compounds that have use as protective agents for reducing the undesired toxic effects of certain drugs, as well as various other medicinal uses.
- Sodium 2-mercaptoethane sulfonate (mesna; Mesnex"; Uromitexan ® ) is an approved drug in the United States and elsewhere for reducing the toxicity of certain antineoplastic alkylating agents, and has been shown to be particularly useful in reducing the acrolein mediated toxicity of cyclophosphamide and ifosfamide.
- derivatives of mesna and dimesna have been synthesized in which the sulfonate groups have been replaced with phosphonate groups, and the length of the alkane chain has been modified.
- Other known derivatives of mesna and dimesna include hydroxylated derivatives as well as thioethers and other related compounds.
- Dimesna is the preferred drag for the reduction of the toxicity of platinum complex and other antineoplastic agents because of its stability in the less reactive disulfide form while in the slightly basic environment of the blood.
- the present invention provides for new and novel salts of dimesna having the following formula I: (D
- R 1 is formula II:
- R 2 is -SO 3 Y
- R 3 is hydrogen or lower alkyl
- R 4 is C 1 -C 6 alkylene or a bond
- R 5 is C 1 -C 6 alkylene or a bond
- X is oxygen or sulfur or X is a bond
- Y is selected from one of the group consisting of a group I metal ion, a group II metal ion, selenium ion; an L-amino acid residue; and an ammonium ion; or a pharmaceutically acceptable salt thereof.
- the novel compounds of this invention will be useful as toxicity reducing agents when administered in combination with many classes of antineoplastic agents.
- the compounds will be utilized as therapeutic and/or palliative agents in the treatment of sickle cell disease, as antidotes for heavy metal poisoning, radiation exposure, free radical elimination, and the like.
- the present invention also provides for pharmaceutical formulations of the formula I compounds.
- the formulations include the formula I compound as active ingredient, along with one or more pharmaceutically acceptable excipients, diluents and/or solvents.
- the formulations may be prepared for either oral or parenteral administration to the patient. Accordingly, it is a principal object of this invention to provide for novel medicinally useful compounds that have pharmaceutical applications in one or more therapeutic fields. Other objects will become apparent upon reading the following specification.
- a C 1 -C 6 alkylene is defined as a bridging moiety formed by 1 to 6 -CH 2 - groups.
- alkylene unless otherwise specified, defines an alkylene moiety having 1 to 8 carbon atoms (i.e., C 1 -C 8 ).
- lower alkyl defines an alkyl group having 1 to 8 carbon atoms (i.e., C 1 -C 8 ).
- the compounds of the present invention are novel disulfide salts, and have the following general formula I:
- R 2 is -SO 3 Y;
- R 3 is hydrogen or lower alkyl;
- R 4 is C 1 -C 6 alkylene or a bond
- R 5 is C 1 -C 6 alkylene or a bond
- X is oxygen or sulfur or X is a bond
- Y is selected from one of the group consisting of a group I metal ion, a group II metal ion, selenium ion; an L-amino acid residue; and an ammonium ion; or a pharmaceutically acceptable salt thereof.
- Preferred derivatives of the above-mentioned compound include those where Y is calcium, selenium, strontium, silver, gold, or magnesium; L-lysine, L-arginine or L-glutamate; or ammonium ion.
- a preferred disulfide salt of the present invention possesses the following structural formula:
- R 1 is formula II:
- R 2 is -SO 3 Y;
- R 3 is hydrogen;
- R 4 is C 2 -C 4 alkylene or a bond;
- R 5 is C 2 -C 4 alkylene or a bond; and
- X is oxygen or sulfur or X is a bond;
- Y is selected from one of the group consisting of a group I metal ion, a group II metal ion, selenium ion; an L-amino acid residue; and an ammonium ion; or a pharmaceutically acceptable salt thereof.
- Preferred derivatives of the above-mentioned compound include those where Y is calcium, selenium, strontium, silver, gold, or magnesium; L-lysine, L-arginine or L-glutamate; or ammonium ion.
- a more preferred disulfide salt of the present invention possesses the following structural formula: (D
- R 1 is formula II: (II)
- R 2 is -SO 3 Y;
- R 3 is hydrogen;
- R 4 is (-CH 2 -O 2 ;
- R 5 is (-CH 2 -) 2 ;
- X is sulfur
- Y is selected from one of the group consisting of a group I metal ion, a group II metal ion, selenium ion; an L-amino acid residue; and an ammonium ion; or a pharmaceutically acceptable salt thereof.
- Preferred derivatives of the above-mentioned compound include those where Y is calcium, selenium, strontium, silver, gold, or magnesium; L-lysine, L-arginine or L-glutamate; or ammonium ion.
- the formula I compounds are novel salts of dimesna 1, which has been shown to reduce the neurotoxicity associated with various taxane and platinum agents, as well as reducing the nephrotoxicity associated with cisplatin. Both dimesna 1 and the novel formula I salts are also predicted to be efficacious in detoxifying additional platinum complex agents, as well as many other antineoplastic drugs.
- the compounds of formula I have usefulness against a variety of other conditions, such as heavy metal poisoning, sickle cell disease, radiation exposure, and many other similar conditions where free radicals are commonly present.
- the formula I compounds may be administered in any convenient dosage form, with the preferred formulations adapted for oral (PO) or intravenous (IV) administration.
- dimesna has been administered intravenously to mice and dogs in doses higher than the accepted oral LD 50 for common table salt (i.e., 3,750 mg/kg), with no adverse effects, hi Phase I clinical trials, dimesna has also been safely administered to humans in doses exceeding 40 g/m 2 .
- Preferred oral formulations include tablets and gelatin capsules, containing an effective amount of the formula I compound, while parenteral formulations are dissolved completely in distilled water prior to administration.
- Preferred dosage amounts will depend upon the purpose of the administration, with the usual recommended dose ranging from 10 mg/kg to 1,000 mg/kg.
- 2,2'-Dithiobis ethane sulfonyl chloride (15.0 g, 47 mmol) was dissolved in a mixed solution of acetonitrile (100 mL) and water (30 mL). The reaction solution was stirred at room temperature for five days until no more sulfonyl chloride was detected. The reaction solution was then concentrated by rotary evaporation at elevated temperature to remove the volatile acetonitrile solvent and as much water as possible. The remaining aqueous solution was washed with dichloromethane (2 x 50 mL) and dried under high vacuum to give 12.7 g of disulfonic acid (96% yield). The product existed as a semi-solid form and was highly hygroscopic. It readily turned to a viscous liquid once exposed to air. No significant impurity was detected in the product by either NMR or HPLC.
- R 6 is an alkylene
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2007003174A MX2007003174A (en) | 2004-09-21 | 2005-09-21 | Medicinal disulfide salts. |
CA2580802A CA2580802C (en) | 2004-09-21 | 2005-09-21 | Medicinal disulfide salts |
EP05801177A EP1797031A4 (en) | 2004-09-21 | 2005-09-21 | Medicinal disulfide salts |
JP2007532635A JP5015781B2 (en) | 2004-09-21 | 2005-09-21 | Pharmaceutical disulfide salts |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/945,809 US7282602B2 (en) | 2004-09-21 | 2004-09-21 | Medicinal disulfide salts |
US10/945,809 | 2004-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006034327A1 true WO2006034327A1 (en) | 2006-03-30 |
Family
ID=36074969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/033774 WO2006034327A1 (en) | 2004-09-21 | 2005-09-21 | Medicinal disulfide salts |
Country Status (7)
Country | Link |
---|---|
US (1) | US7282602B2 (en) |
EP (1) | EP1797031A4 (en) |
JP (1) | JP5015781B2 (en) |
CN (1) | CN101076513A (en) |
CA (1) | CA2580802C (en) |
MX (1) | MX2007003174A (en) |
WO (1) | WO2006034327A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3094619A4 (en) * | 2014-01-13 | 2017-06-14 | The General Hospital Corporation | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011067653A1 (en) * | 2009-12-04 | 2011-06-09 | Carlo Ghisalberti | Oral compositions for use in the mercury intoxication from dental amalgam |
JP6271233B2 (en) * | 2013-11-29 | 2018-01-31 | ローム・アンド・ハース電子材料株式会社 | Surface treatment liquid |
CA3164346A1 (en) * | 2020-01-10 | 2021-07-15 | Aditya Kulkarni | Method for determining sensitivity to 2,2'-dithio-bis-ethane sulfonate |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5661188A (en) * | 1995-06-07 | 1997-08-26 | Medical Research Foundation and Infrastructure Development for Health Services--Nahariya Hospital Branch | Therapeutic uses for sodium 2-mercaptoethanesulphonate (mesna) |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE593047A (en) * | 1959-07-17 | |||
DE2025538A1 (en) * | 1970-04-02 | 1971-10-21 | Lokomotivbau Elektrotech | Copper acid electrodeposition using brightener composition |
BE788685A (en) * | 1971-09-13 | 1973-03-12 | Agfa Gevaert Nv | DEVELOPMENT OF CONTRASTRICH SILVER HALOGENIDE EMULSIONS FOR GRAPHIC PURPOSES |
DD122086A1 (en) * | 1975-06-16 | 1976-09-12 | ||
IT1185551B (en) * | 1985-04-15 | 1987-11-12 | Schering Spa | PHARMACEUTICAL COMPOSITIONS BASED ON MERCAPTOETHANE SULPHONE ACID WITH THERAPEUTIC ACTIVITY, ORGANIC SALINE DERIVATIVES OF MERCAPTO ETHAN SULPHONIC ACID USEFUL FOR SUCH COMPOSITIONS AND RELATED PREPARATION PROCEDURE |
DE4032864A1 (en) * | 1990-10-13 | 1992-04-16 | Schering Ag | ACIDIC BATH FOR THE GALVANIC DEPOSITION OF COPPER COVERS AND METHODS USING THIS COMBINATION |
DE4127821A1 (en) * | 1991-08-23 | 1993-02-25 | Basf Ag | DISULFIDES, METHOD FOR THE PRODUCTION AND USE THEREOF |
US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
AU712548B2 (en) * | 1996-09-23 | 1999-11-11 | Bionumerik Pharmaceuticals, Inc. | Reducing toxic effects of carboplatin using dithioethers |
DK0934261T3 (en) * | 1996-10-01 | 2001-11-19 | Bionumerik Pharmaceuticals Inc | Process for the preparation of dithiobis alkanesulfonates and phosphonates |
US6160167A (en) * | 1998-04-21 | 2000-12-12 | Bionumerik Pharmaceuticals, Inc. | Mercaptans and disulfides |
JP3124523B2 (en) * | 1999-01-28 | 2001-01-15 | 日本エレクトロプレイテイング・エンジニヤース株式会社 | Copper plating method |
KR20020029626A (en) * | 2000-10-13 | 2002-04-19 | 마티네즈 길러모 | Electrolyte |
JP2003072231A (en) * | 2001-09-06 | 2003-03-12 | Oji Paper Co Ltd | Ink jet recording sheet |
US6504049B1 (en) * | 2002-04-30 | 2003-01-07 | Bionumerik Pharmaceuticals, Inc. | Process for synthesizing pharmaceutically active disulfide salts |
WO2004059040A1 (en) * | 2002-12-25 | 2004-07-15 | Nikko Materials Co., Ltd. | Copper electrolytic solution containing quaternary amine compound polymer of specified skeleton and organic sulfur compound as additives and electrolytic copper foil produced therewith |
JP2005048256A (en) * | 2003-07-30 | 2005-02-24 | Asahi Denka Kogyo Kk | Additive for copper plating, copper plating bath and copper plating method |
JP2006104134A (en) * | 2004-10-06 | 2006-04-20 | Asahi Denka Kogyo Kk | Method for producing disulfides |
JP4750486B2 (en) * | 2005-07-06 | 2011-08-17 | 株式会社Adeka | Electrolytic copper plating additive, electrolytic copper plating bath containing the additive, and electrolytic copper plating method using the plating bath |
-
2004
- 2004-09-21 US US10/945,809 patent/US7282602B2/en active Active - Reinstated
-
2005
- 2005-09-21 CN CNA200580035465XA patent/CN101076513A/en active Pending
- 2005-09-21 CA CA2580802A patent/CA2580802C/en not_active Expired - Fee Related
- 2005-09-21 EP EP05801177A patent/EP1797031A4/en not_active Withdrawn
- 2005-09-21 JP JP2007532635A patent/JP5015781B2/en active Active
- 2005-09-21 WO PCT/US2005/033774 patent/WO2006034327A1/en active Application Filing
- 2005-09-21 MX MX2007003174A patent/MX2007003174A/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5661188A (en) * | 1995-06-07 | 1997-08-26 | Medical Research Foundation and Infrastructure Development for Health Services--Nahariya Hospital Branch | Therapeutic uses for sodium 2-mercaptoethanesulphonate (mesna) |
Non-Patent Citations (2)
Title |
---|
BREZINZSKA ET AL: "Disulfides. 1. Synthesis Using 2,2'-Dithiobis (benzothiazole).", J OF ORGANIC CHEMISTRY., vol. 59, 1994, pages 8239 - 8244, XP002050050 * |
See also references of EP1797031A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3094619A4 (en) * | 2014-01-13 | 2017-06-14 | The General Hospital Corporation | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin |
EP3626707A1 (en) * | 2014-01-13 | 2020-03-25 | The General Hospital Corporation | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin |
US10758569B2 (en) | 2014-01-13 | 2020-09-01 | The General Hospital Corporation | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin |
Also Published As
Publication number | Publication date |
---|---|
CA2580802C (en) | 2012-11-20 |
EP1797031A4 (en) | 2009-12-16 |
CN101076513A (en) | 2007-11-21 |
US7282602B2 (en) | 2007-10-16 |
US20060063949A1 (en) | 2006-03-23 |
JP5015781B2 (en) | 2012-08-29 |
CA2580802A1 (en) | 2006-03-30 |
JP2008513503A (en) | 2008-05-01 |
EP1797031A1 (en) | 2007-06-20 |
MX2007003174A (en) | 2008-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4602037A (en) | Xanthates and antiviral use thereof | |
US4383994A (en) | Homocysteine thiolactone salts and use thereof as anti-neoplastic agents | |
US6160167A (en) | Mercaptans and disulfides | |
DE68921298T2 (en) | Heart-protecting tocopherol-like compounds. | |
CA2580802C (en) | Medicinal disulfide salts | |
KR0178794B1 (en) | Oxidized-type glutathione alkyl ester | |
KR910006309A (en) | Antiviral drugs with phospholipids and phospholipid derivatives as active ingredients | |
JP4936898B2 (en) | Synthesis method of disulfides | |
US7829117B2 (en) | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents | |
GB1585963A (en) | Aryl sulphur compounds | |
PL184861B1 (en) | Improvement in tolerance of pharmaceutically active beta-amino acids | |
PL128998B1 (en) | Process for preparing novel 2-amino-3-benzoylphenylacetamides and their derivatives | |
EP2235022B1 (en) | Dimeric derivatives of artemisinin and application in anticancer therapy | |
EP0326326B1 (en) | Cysteine derivatives | |
KR960029319A (en) | 4-aminobenzoylguanidine derivatives | |
IE68060B1 (en) | Nitratoalkanecarboxylic acid derivatives a process for their preparation use thereof and medicaments containing them | |
CA1174978A (en) | Xanthates | |
US6034126A (en) | Method for treating glycol poisoning | |
GB2054582A (en) | Water soluble derivatives of 6,6-methylene - bis - (2,2,4-trimethyl - 1,2-dihydroquinoline) and process for the preparation thereof | |
US5736530A (en) | Guanylic acid derivatives and their use as drugs | |
IE41495B1 (en) | Dihydroapovincaminic acid amide | |
EP0456843A1 (en) | Bornyl and isobornyl carboxylic esters of condensed tetrahydroquinoxalines as antiviral agents | |
EP0202854A2 (en) | Phosphine gold compounds | |
CS227333B2 (en) | Method of preparing alkali metal salts of sulphonic acids and sulphonamide 6,6-methylene-bis(2,2,4-trimethyl-1,2-dihydroquinolinone) derivatives and dimer and trimer condensation products thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/003174 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2580802 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007532635 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2350/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005801177 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580035465.X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005801177 Country of ref document: EP |